✦ LIBER ✦

Phase II study of carboxyamidotriazole in patients with advanced renal cell carcinoma refractory to immunotherapy : E4896, an Eastern Cooperative Oncology Group study

✍ Scribed by Janice P. Dutcher; Larry Leon; Judith Manola; David M. Friedland; Bruce Roth; George Wilding

Publisher: John Wiley and Sons
Year: 2005
Tongue: English
Weight: 93 KB
Volume: 104
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.21473

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II trial of trimetrexate for patie

Phase II trial of trimetrexate for patients with advanced gastric carcinoma : An Eastern Cooperative Oncology Group Study (E1287)

✍ Ramesh K. Ramanathan; Stuart Lipsitz; Robert F. Asbury; Raman Qazi; Bernard R. G 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 65 KB 👁 2 views

## BACKGROUND. A Phase II study was conducted to evaluate the response, duration of response, and duration of survival of patients with measurable gastric carcinoma treated with trimetrexate (TMTX) who had not had prior chemotherapy. ## METHODS. Thirty-three patients with unresectable or metast

Phase II study of paclitaxel plus carbop

Phase II study of paclitaxel plus carboplatin in patients with advanced carcinoma of the urothelium and renal dysfunction (E2896) : A trial of the Eastern Cooperative Oncology Group

✍ David J. Vaughn; Judith Manola; Robert Dreicer; William See; Ralph Levitt; Georg 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 74 KB 👁 2 views

## Background: Chemotherapy options for the patients with advanced urothelial carcinoma and renal dysfunction are limited. the authors performed a phase ii trial of paclitaxel plus carboplatin in patients with advanced carcinoma of the urothelium and renal dysfunction. ## Methods: Forty-two patie

A Phase II study of all-trans-retinoic a

A Phase II study of all-trans-retinoic acid plus cisplatin and etoposide in patients with extensive stage small cell lung carcinoma : An Eastern Cooperative Oncology Group study

✍ Gregory P. Kalemkerian; Michael Jiroutek; David S. Ettinger; John A. Dorighi; Da 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 84 KB 👁 2 views

The contents of this article are solely the responsibility of the authors and do not necessarily represent the official views of the National Cancer Institute.

A phase II trial of interferon-α and 5-f

A phase II trial of interferon-α and 5-fluorouracil in patients with advanced renal cell carcinoma: A Southwest Oncology Group study

✍ Laurence Elias; Brent A. Blumenstein; Julie Kish; Robert C. Flanigan; James L. W 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 355 KB 👁 1 views

## BACKGROUND. Renal cell carcinoma is a common neoplasm that is often refractory to treatment. It is occasionally responsive to immunoniodulating agents including interferon-a, which enhances the effects of 5-fluorouracil upon cells. Combinations of these two drugs have been most frequently tested

A randomized Phase II trial of echinomyc

A randomized Phase II trial of echinomycin, trimetrexate, and cisplatin plus etoposide in patients with metastatic nonsmall cell lung carcinoma : An Eastern Cooperative Oncology Group Study (E1587)

✍ Alex Y. Chang; KyungMann Kim; Hélène Boucher; Philip Bonomi; James A. Stewart; D 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 96 KB 👁 2 views

## Background: Patients with metastatic nonsmall cell lung carcinoma (nsclc) usually have a poor prognosis. a chemotherapy regimen containing cisplatin is commonly used for symptom palliation. echinomycin is a potent bifunctional intercalator of double-strand dna; trimetrexate is a new derivative o

A phase II study of 5-fluorouracil, leuc

A phase II study of 5-fluorouracil, leucovorin, and interferon-α in the treatment of patients with metastatic or recurrent gastric carcinoma : An Eastern Cooperative Oncology Group study (E5292)

✍ Gary R. Hudes; Stuart Lipsitz; Jean Grem; Mary Morrisey; Louis Weiner; John W. K 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 68 KB 👁 1 views

Chemotherapy has a limited impact on adenocarcinoma of the stomach. Although biochemical modulation of 5-fluorouracil (5-FU) by leucovorin (LV) and interferon-␣ (IFN-␣) has improved the outcomes of patients with metastatic colorectal carcinoma compared with 5-FU alone, this approach has not been ext